Taking into consideration the benefits of creating TGF-β resistant CAR-T cells, a phase 1 clinical trial was conducted to assess the effectiveness of PSMA-targeting CAR-T cell therapy engineered with dnTGF-βRII in treating metastatic castration-resistant prostate cancer [96]. The gene discussed is FOLH1; the disease is prostate cancer.